Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive detection technology for biophysical characterization of small molecule interactions with complex drug targets. This includes integral membrane proteins and biochemically intractable target binding assays in native-like, free-solution environments — no tags or tethering.
Conformational change is the hallmark of protein dynamics and are intimately related to protein function. BSI detects binding-induced target conformational change with high specificity and sensitivity. It allows unlabeled binding affinity measurement, target engagement verification and mechanism-of-action elucidation in a single assay platform, vital to informing pharmacology and medicinal chemistry drug discovery efforts.
MSI currently offers the TruBind™ BSI System 100 and TruBind Assay Services to pharmaceutical companies.
Please send us an email or give us a call at (615) 938-7050 in North America or +49 (171) 760-4450 in Europe to find out how MSI can help accelerate your assay development and screening efforts.
Visit our booth #1619 and attend our Tuesday Tutorial on Conformation-Sensitive Assay Detection for Accelerated Drug Discovery Research. Learn about the superior analytical power of TruBind™ Back Scattering Interferometry (BSI) technology for molecular interaction studies.
TRY A LOW-RISK, HIGH-RETURN DRUG DISCOVERY PROJECT
Take advantage of our success-based drug-target characterization services including ortho- and allosteric membrane bound proteins, receptors, ion channels, protein complexes — your toughest targets.
